New Views of Old Proteins: Clarifying the Enigmatic Proteome

Authors
Kristin E. Burnum-Johnson, Thomas P. Conrads, Richard R. Drake, Amy E. Herr, Ravi Iyengar, Ryan T. Kelly, Emma Lundberg, Michael J. MacCoss, Alexandra Naba, Garry P. Nolan, Pavel A. Pevzner, Karin D. Rodland, Salvatore Sechi, Nikolai Slavov, Jeffrey M. Spragins, Jennifer E. Van Eyk, Marc Vidal, Christine Vogel, David R. Walt, and Neil L. Kelleher

Correspondence
kristin.burnum-johnson@pnnl.gov; n-kelleher@northwestern.edu

In Brief
Capturing the biology of proteins will require improved technologies to readout their composition in space and time. Developing these improved technologies presents a major opportunity for biomedical research. How might we proceed in the decades ahead?

Highlight
• How functional proteomics tools, methods, and datasets can be integrated to accelerate the development of comprehensive spatiomolecular tissue maps that generate new biological insights?
New Views of Old Proteins: Clarifying the Enigmatic Proteome

Kristin E. Burnum-Johnson 1,*, Thomas P. Conrads 2, Richard R. Drake 3, Amy E. Herr 4, Ravi Iyengar 5, Ryan T. Kelly 6, Emma Lundberg 7, Michael J. MacCoss 8, Alexandra Naba 9, Garry P. Nolan 10, Pavel A. Pevzner 11, Karin D. Rodland 12, Salvatore Sechi 13, Nikolai Slavov 14, Jeffrey M. Spraggins 15, Jennifer E. Van Eyk 16, Marc Vidal 17, Christine Vogel 18, David R. Walt 9, and Neil L. Kelleher 20,*

All human diseases involve proteins, yet our current tools to characterize and quantify them are limited. To better elucidate proteins across space, time, and molecular composition, we provide a >10 years of projection for technologies to meet the challenges that protein biology presents. With a broad perspective, we discuss grand opportunities to transition the science of proteomics into a more propulsive enterprise. Extrapolating recent trends, we describe a next generation of approaches to define, quantify, and visualize the multiple dimensions of the proteome, thereby transforming our understanding and interactions with human disease in the coming decade.

THE PROTEOME IS EXTREMELY COMPLEX

Proteins are the primary conduit connecting our genes to complex traits including the diseases that afflict us. While the genome provides the “biological script,” proteins run and fill it with life. Given this critical role, the enormous complexity of the proteome, and the pace of technology development, we highlight strategies and opportunities for proteomics in the coming decades. Compared with the deep coverage of DNA in the genome through sequencing, our ability to detect proteins achieves only ~0.1x coverage of the proteome (1). To fill this proteomic gap in the coming years, we argue for accelerated technology development, concerted efforts across laboratories, and large consortia with meaningful data integration. These advances will need to match the complexity of our biology, enabling the emergence of new enterprises to boost detection and develop interventions that will reliably extend our life spans and quality of life.

The immense complexity of the proteome arises from the fact that each gene produces several protein variants, termed “proteoforms,” far beyond what can be predicted from DNA sequence (Fig. 1). The proteoform paradigm describes the composition of protein molecules arising from ~250 types of post-translational modifications (PTMs) (2), alternative transcriptions or translation start sites, splicing, or amino acid changes (Fig. 1). A single cell easily encompasses hundreds of thousands of different proteoforms reflecting the true chemical diversity of protein molecules (3, 4), each having the potential to alter structure, function, and interactions. While the number of theoretically possible proteoforms is extremely large (3, 4), existing methods detect fewer than 10,000 proteoforms in a typical cell sample.

From the 1The Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington, USA; 2Inova Women’s Service Line, Inova Health System, Falls Church, Virginia, USA; 3Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina, USA; 4Department of Bioengineering, University of California, Berkeley, California, USA; 5Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 6Department of Chemistry and Biochemistry, Brigham Young University, Provo, Utah, USA; 7Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden; 8Department of Genome Sciences, University of Washington, Seattle, Washington, USA; 9Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, Illinois, USA; 10Department of Pathology, Stanford University, Stanford, California, USA; 11Department of Computer Science and Engineering, University of California at San Diego, San Diego, California, USA; 12Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA; 13National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA; 14Department of Bioengineering, Northeastern University, Boston, Massachusetts, USA; 15Department of Cell and Developmental Biology, Mass Spectrometry Research Center, Vanderbilt University, Nashville, Tennessee, USA; 16Advanced Clinical Biosystems Institute in the Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA; 17Department of Genetics, Harvard University, Cambridge, Massachusetts, USA; 18New York University Center for Genomics and Systems Biology, New York University, New York, New York, USA; 19Department of Pathology, Harvard Medical School, Brigham and Women’s Hospital, Wyss Institute at Harvard University, Boston, Massachusetts, USA; 20Department of Chemistry, Northwestern University, Evanston, Illinois, USA

The authors were participants in an NIH Workshop on Functional and Integrative Proteomics.

*For correspondence: Kristin E. Burnum-Johnson, kristin.burnum-johnson@pnnl.gov; Neil L. Kelleher, n-kelleher@northwestern.edu.
Given the complexity of proteins, it is unsurprising that RNA abundance or ribosome-bound mRNA is imperfect surrogate for protein abundance. RNA abundance ranges over ~4 orders of magnitude in cells, whereas proteoforms range over ~7 orders of magnitude and even over 10 in body fluids (5). Researchers use diverse proteomic technologies to identify and quantify proteins, and the analytical sensitivity, reproducibility, and specificity of platforms are extensive. These tools enable both discovery experiments (where emphasis is on identifying large numbers of proteins) and targeted measurements that focus on individual proteins, pathways, and/or certain classes such as membrane proteins. Ongoing innovation in spatial proteomics and multiplexing of compositional proteomics continue to improve our ability to probe the approximately half of the 20,000 genes expressed into detectable proteins in a given cell type. These developments have substantially advanced our functional and mechanistic insights of proteins (6).

Looking forward, one significant goal in the coming decades is to increase the efficiency of and access to different proteomic platforms while also decreasing cost. To do so, we need to prioritize technology development to deliver diverse data types of high value to the community. Efforts are under way; for example, mapping projects that use multiplexed protein measurements with single-cell resolution via antibody-based tissue imaging. The Human Protein Atlas (7) and the Human BioMolecular Atlas Program (HuBMAP) (8) are examples of such efforts. But, if proteomics are to capture biological complexity in its dynamics and relationships across scales, we need to upgrade our ability to sample proteoforms spatially, their complexes in organelles, and in regions of phase transition to make functional assertions with high confidence. Such effort will require creating technologies capable of molecular deconvolution from millimeters to nanometers and their temporal dynamics from seconds to the human life span.

Another significant goal will involve integration of such proteoform data with other multiomic data. Such “spatial multiomics data” will allow us to infer emergent properties of whole organisms, rather than investigating one aspect at a time. Integration is still challenging because of missing values, different properties of different data types, and the fact that defining precise proteoforms is challenging. Still, we believe that breakthroughs for these two goals—new technology combined with meaningful data integration—are achievable within the next 10 years.

**PTMs are Major Drivers of Proteoform Diversity**

**Top–Down Proteomics**—A first step toward comprehensively understanding proteome complexity is the efficient detection of proteoforms and their PTMs. PTMs are one of the major routes to produce proteoforms, and many proteins have multiple modifications, but it is still unclear which of these PTMs are functional and which are passengers or “bystanders.”

With “top–down” mass spectrometry (MS), intact proteoforms and their assemblies are analyzed, thereby directly informing on co-occurring events (i.e., PTMs, isoforms, or mutations). This approach has some advantages over peptide-centric “bottom-up” approaches described later, including (9) resolving the protein inference problem (10), identifying isoforms directly, and retaining both stoichiometry and the combinatorial occurrence of PTMs (Fig. 2) (9). Because so many questions about PTMs remain unanswered,
expanding this approach will improve the efficiency of detection and assignment of function to all protein variants and their modifications in the coming decade.

**Bottom–up Proteomics**—In detecting thousands of peptides and PTMs efficiently, bottom–up proteomics uses proteases to digest the proteome and is the current “to-go” platform for discovery proteomics. Unlike whole proteins, many peptides are easily fractionated, ionized, and fragmented via liquid chromatography–tandem MS methods. In addition, several options exist for collecting information on peptides and modified peptides and for infusing spatial information (Fig. 3, upper right) (11). However, data from bottom–up approaches remain limited in sequence coverage of individual proteins and coverage of the single-cell proteome. For example, because of the protein inference problem, biological signals are masked by combining peptides into a single protein quantity, losing information on combinatorial effects (12). Targeted MS assays, such as selected reaction monitoring, can precisely identify peptide sequences and specific PTMs to achieve absolute quantification and probe known proteoforms (13, 14). Future developments should continue by combining top–down with bottom–up strategies in an integrated approach for robust quantitation of isoforms and PTMs.

**Proteomics Goes Single Cell (and Single Molecule)**

**Single-Cell Proteomics**—Tissues are heterogeneous mosaics of cells in different physiological stages, requiring single-cell analysis. However, given that we cannot amplify proteins and their concentrations cover a large dynamic range, single-cell proteomics is challenging. Some single-cell proteomics methods employing antibodies or other affinity reagents have existed for decades (Fig. 3, left). While these methods have improved significantly in power and sophistication (15), the newest developments via bottom–up MS have clearly expanded the horizon for single-cell proteomics (16–27).

Over the last 4 years, mass spectrometric methods have advanced from quantifying a few 100 proteins per cell to quantifying more than 1000 proteins per cell, with thousands of proteins quantified across datasets at a throughput of >200 single cells per day (Fig. 3, upper right) (28, 29). One enabling technology making such in-depth single-cell and “low-input” proteome profiling possible is multiplexed analysis of single cells labeled with isobaric mass tags and combined with an isobaric carrier (26) to enhance throughput and MS/MS peptide sequence identification (30). Miniaturization of sample preparation volumes to nanoliter or low-microliter levels has minimized surface losses and enhanced reaction kinetics (31, 32). In addition, miniaturization of liquid chromatography (25) and capillary electrophoresis (33) separations have boosted prospects, even adding peptide selectivity to the workflow (24, 27). However, future approaches still need to achieve higher coverage and throughput more comparable to those of single-cell RNA-Seq. We posit that this will be achievable given the rate of improvement through advances in different steps of the workflow. Integration of proteomics data with other single-cell modalities, such as small conditional RNA-Seq, have already provided initial results (16, 20, 28). We imagine that within the next 5 years, proteomics will cover >5000 proteins from thousands of single cells per day, with linked information on transcripts.

**Single-Molecule Sequencing**—Another promising area of technology development includes single-molecule protein sequencing and proteoform detection (34–37). These approaches have the potential to be disruptive and to impact single-cell protein analysis, with sequencing demonstrated only on synthetic peptides thus far. Intriguingly, there have been major increases in private sector investments in this general area over the past year, creating a palpable sense that this could be the decade of breakthroughs in single-molecule protein measurement and sequencing.

Such technologies operative on single molecules will encounter the challenge of proteoform diversity expressed in human biology (Fig. 1). Therefore, they would benefit from better general compositional definition of the expressed proteome, prior to investigating the existence of different
proteoforms in individual cells. Indeed, amassing a reference set of human proteoforms has been proposed (6, 38, 39) using both cell- and gene-based approaches (39). Using output of the Human Cell Atlas, HuBMAP, and other consortia, comprehensive maps of human cell types will allow the proteome of each cell type to be defined. Assuming 5000 cell types and 1 million proteoforms in each cell type, such a human proteoform atlas would involve approximately 5 billion measurements, with perhaps approximately 50 million unique proteoforms needing to be asserted and mapped in the coming decade (39). Such efforts will only be possible based on the output of current atlasing efforts, providing reference sets of what proteoforms are actually present and where.

Single-Cell and Single-Molecule Immunoassays—Complementing methods for proteome-wide characterization, targeted assays using affinity reagents can accurately detect and quantify specific proteins. While often targeting fewer proteins, they achieve far higher throughput than nontargeted approaches. Furthermore, many proteins of interest in the human proteome are below the limit of detection of current MS methods and conventional immunoassays. One major group of targeted approaches includes immunoassays that are designed to detect known protein targets, with target identities informed by a priori discovery proteomics or driven by biological hypotheses. At the single-cell level, the formats are diverse and include immunohistochemistry, flow cytometry, mass cytometry, and various formats for multiplexed antibody-based imaging. Arrays of affinity reagents are also available for limited operation in discovery mode; use of these platforms is likely to increase in the coming decades.

Over the last 2 decades, miniaturization of single-cell immunoassays has improved to the point where proteins in thousands of samples can now be processed in parallel, while using far less time, sample, and reagents. Performance improvements stem from the underlying physics at miniature scale, and microfluidic approaches have enabled new assay designs (40). Microdevices afford scalable means to precisely compartmentalize individual cells, with the use of both droplets (41) and microwells being common strategies (42). Furthermore, ultrasensitive single-molecule technologies already access proteins at picomolar and femtomolar concentrations in the single-protein regime using digital immunoassays like SiMPull (43), SiMoAs (44), and droplet-based assays (45, 46). While not providing proteoform-level specificity, these single-cell frameworks are powerful for multimodal same-cell measurements (47, 48). Scrutinizing the protein content of lysates from thousands of individual organelles is viable today using microfluidic devices to overcome shortcomings of single capillary systems for single-cell (49, 50), subcellular (51), and multimodal (52, 53) immunoblotting.

Given new developments in droplet microfluidics, microfluidic imaging cytometry (41), and subcellular immunoblotting, we envision targeted single-cell proteomics to push two new frontiers: (1) monitoring protein expression in specific

---

**Fig. 3. Multiple approaches for assessment of proteins in single cells.** Antibody specificity dictates the protein detection specificity for technologies depicted in orange. bottom-up Mass Spectrometry, measures peptides; CODEX, codetection by antibody indexing; CyTOF, mass cytometry; nanoDESI, spatially resolved desorption by electrospray; PEA, proximity extension assay; PLAYR, proximity ligation assay for RNA; REAP, a rapid, efficient, and practical cell processing method; sc, single cell; top-down mass spectrometry, measures proteoforms.
cellular compartments and (2) multimodal single-cell analyses that integrate proteomics with other omics data. While selective target detection and antibody availability remain an inherent limitation of immunoassays, we foresee a tremendous opportunity for immunoassays to become proteoform specific across diverse cells. We posit that clever immunoassay strategies that enhance analytical specificity (54, 55) will help translate proteoform knowledge into scalable single-molecule assays. We project that by 2030, innovations in this area will move such analyses to cost-effective benchtop instruments usable in diverse settings. Analysis of thousands of individual cells per assay, with specificity for hundreds of currently undiscernible proteoforms within each cell, is possible. Absolute, not simply relative, quantification of each proteoform beckons.

Availability and Validity of Affinity Reagents—Many assays in basic and clinical research rely on antibodies. However, there are proposed (56), but no widely accepted guidelines to determine the validity of these reagents. Furthermore, many recent publications have highlighted that commercial antibodies can fail to detect the intended target in diverse sample types. (57, 58) The utility in biological and biomedical research of affinity reagents for characterizing and quantifying proteins and peptides is central; however, it also should elevate the challenge in validating and reproducing many of the antibody-based assays published each year. For this purpose, increasing effort will be required to improve the rigor and reproducibility of antibody-based assays, (59), e.g. the antibody registries specific and unique identifiers for reagents. (60).

The proteomics field would greatly benefit from such antibody database and library, in particular if it is open source. Antibodies are expensive, and reducing their cost through a public database would allow researchers to devote more of their funding to other materials and maximize findings. To enhance reproducibility and operational efficiency, recombinant antibodies with known sequences would create a long-lasting and reproducible resource across laboratories (59). Increasingly, antibody sequencing and characterization using proteomics is on the rise (61, 62), making an open-source library of antibodies even more feasible in the coming decade.

Another important resource for proteomics of the future would be a proteoform-specific library of affinity reagents covering as many products of human genes as possible. Moving forward, we should promote gene-specific probes and create a generation of proteoform-aware PTM-recognizing affinity reagents (e.g., phosphorylation site–specific antibody reagents) (63). Creating such a resource will be a massive undertaking, but limited scope pilots in which antibodies to known proteoforms of key proteins hubs in cellular regulatory networks (c-Myc, p53, NFF06BB, histones, etc) would be a very valuable resource and important next step. Construction of such a library of proteoform-specific antibodies, with known epitope-binding specificity, critically depends on the reproducibility, specificity, and scalability with which multiple antibodies can probe multiple epitopes and PTMs on proteoforms.

Thinking Outside the Cell: Extracellular Matrix, Body Fluids, and Extracellular Communication

Not only does one need to understand the single-cell proteome but also it is necessary to quantify the cellular environment and context. Quantification and defining extracellular communication and the cellular environment is required to infer tissue and organ function. The extracellular matrix (ECM) contains highly glycosylated and crosslinked proteins that form the scaffold of cellular anchorage and migration (64, 65). The ECM also liberates and sequesters secreted molecules such as growth factors (66). It plays critical roles in development, health, and disease via mechanical and chemical signal transduction. While recent proteomic methods tailored to biochemically unique ECM proteins have led to greater understanding of the ECM proteomes (67–71) in many tissues and organs, these methods cannot fully capture the broad dynamic range of the ECM from low-abundance growth factors to hyperabundant collagens (72). New imaging MS methods using collagenase digestions targeted to the ECM are beginning to address some spatial–temporal aspects (73, 74). To achieve near-complete coverage and single-cell-level profiling of the matrisome and to capture its dynamics, our community will need to (1) expand methods to identify and isolate specific cell and tissue niches (e.g., laser-capture microdissection (75) and imaging MS), (2) develop reagents to enrich for ECM proteins or classes of ECM proteins (e.g., high-affinity antibodies against ECM-specific PTMs or splice variants), (3) use ECM-specific proteases such as elastase and collagenases instead of trypsin, and (4) apply adequate data analysis workflows (76, 77).

Beyond the ECM, the extracellular milieu contains protein-rich fluids (78–80) (e.g., tissue interstitial fluids, serum/plasma, urine, saliva, etc) that present unique challenges when it comes to proteomic profiling. Extracellular vesicles and their protein contents are key mediators of cell communications and regulators of cellular functions (81, 82), including those that can affect “in trans” chemoresistance and angiogenesis in cancer (83). An important activity for advancing proteomics will be to convert ultrtrace analysis into a straightforward deep characterization of extracellular proteomes and to correlate the resulting information with their cells of origin.

The Future Lies in Integration Across Scales

Spatial Information—Be it through networks or other models, future efforts will have to integrate compositional, interactomics, and spatial information on proteoforms to reveal how the proteome drives human physiology. The proteomics toolkit offers a variety of methods for detecting protein–protein interactions that range from direct detection, such as affinity-purification MS, to less direct, such as
correlational profiling. These approaches are relatively low throughput, whereas we need high-throughput methods for sensitive analysis of protein–protein interactions in primary tissues. We put forward a reductionist view in which enough spatial information—in conjunction with other omics data—can define the state, function, and trajectory of a cell within the tissue microenvironment. Approximately 20 spatial proteomics technologies are currently used within the proteomics field (54, 84–91); these approaches can be targeted and multiplexed (e.g., using antibodies) or nontargeted (e.g., MS). Spatial technologies can measure specific protein–protein interactions, subcellular structures, individual cells, and tissue microenvironments within whole organs.

Imaging MS (85, 89, 92) assesses large numbers of glycans, lipids, and metabolites at spatial resolutions of 10 microns (85, 93, 94). At the proteomics level, imaging MS can currently identify >2000 proteins at spatial resolutions of 100 microns (89). Using different proteases and glycosidases, imaging MS also can be integrated with, for example, microscopy of the ECM to evaluate multiple analytes sequentially on the same tissue slice (73, 95). A future challenge will lie in applying these methods to resolve proteoforms down to 1 micron. To do so, major bottlenecks like low proteome coverage (especially for large and low abundance proteins) will need to be overcome.

Other imaging MS approaches we envision would combine artificial intelligence–powered image analysis with automated single-cell laser microdissection and ultrahigh sensitivity MS to link protein abundance to complex cellular or subcellular phenotypes while preserving spatial context. They have successfully identified rare cell states with distinct morphology (96). Spatial proteomics approaches are also commonly combined with magnetic resonance/computed tomography imaging data to assess anatomical features, stained microscopy to assess tissue morphology, multiplexed immunofluorescence approaches to differentiate cell types, and fluorescence in situ hybridization to observe DNA- and RNA-mediated influences. For example, multimodal imaging analyses of the murine spleen and pancreas have resolved pixel-level cellular populations and subregions (94, 97).

Another future challenge with imaging MS lies in tackling subcellular resolution. Exploiting fluorescence-based technologies, multiplexed protein imaging can now detail cell subtypes (Fig. 4). In the future, these protein imaging efforts could also include RNA information. We imagine that the future will bring a new kind of three-dimensional “AtomScope” capable of measuring every atom in a model cell, then reconstructing the structure of single molecules and their assemblies in a bottom-up process. As with single-cell and single-molecule proteomics, such aspirations will benefit from higher quality reference proteomes, structural predictors like AlphaFold, and a greatly improved baseline knowledge about proteoforms, their PTMs, and complexes. With meaningful data integration, models of the future will identify spatial dependencies of compositional data, correlate spatial patterns to specific outcomes, assess relationships between data types to enable predictions across them, and integrate data generated across bulk and single-cell scale. One early example lies in integration of protein imaging with protein–protein interaction data in the multiscale integrated cell model (98) that led to the identification of novel cellular systems.

**Meaningful Data Integration**—Given the aforementioned developments, the way forward is to integrate different data-sets in a biologically informed and statistically robust manner. Such integration will then detect emergent properties of the system as a whole (99) and consider the cell and its proteome as an “ecosystem” in which the sum is more than the parts. One popular method of integration exploits networks, with mathematical approaches available to understand and predict properties (Fig. 5A). Networks include both parts’ lists and interactions among the parts. Constructing such networks will
Fig. 5. Capturing the multidimensional biology of our proteome. A, from a parts lists to interaction mapping and proteoform networks underlying cell-based biology. B, capturing time-resolved human biology at the protein level. Top, depiction of multiple spatiomolecular proteoform images collected over time. Bottom, temporal dynamics vary widely across disease progression (years) across cell differentiation (days) in human bone marrow and blood or through embryogenesis (months).
allow us to understand concepts such as the robustness of a system (the cell) to perturbations (i.e., mutations and loss of the protein) or efficiency and redundancy in signal transduction (i.e., through creation of short paths through a network that prioritize rapid response over versatility). Future work will accommodate different types of nodes (e.g., proteoforms) and different types of edges (e.g., kinase-target interactions or protein–protein interactions in a complex).

We propose that in the coming decades, “filling this network with life” will involve rethinking commonly used terms, for example, that of protein function. While functional descriptions are standardized in a controlled vocabulary such as Gene Ontology (100), we will need to identify more quantifiable definitions (e.g., by the profile of the genetic, physical, or regulatory interactions of a protein). Such definitions would also allow us to measure similarity and changes to proteoform function. For example, once a transcript is spliced, rearranged, and modified, the resulting different proteoforms are expected to mediate divergent functions or behave as alloforms, rather than retain similar functions, or acting as isoforms (101).

Other proteomics integration efforts will need to venture toward other molecule types, such as RNA, or metabolites that are already being captured with spatial resolution (Fig. 5). Existing efforts have already shown the power of such an approach to infer regulatory mechanisms and most tightly connected and therefore potentially most functionally important relationships. For example, integrating complementary RNA, protein, and metabolite in the Kidney Precision Medicine Project has generated many new hypotheses (102). More generalized efforts for multiomics data integration across space and time are exemplified by the Human Tissue Atlas Network (103).

Finally, we propose that the future of proteomics lies not only in integrative network approaches and redefining entities to render them quantifiable but also will include consideration of the combinatorial nature of biological processes. Traditionally, we study one protein or pathway at a time as the cell is otherwise too complex. Including combinatorial action of proteoforms under the same conditions, attacking the same problem (e.g., through aforementioned network approaches) will allow us to truly understand cells and functional tissue units as systems driving life processes such as those shown in Figure 5B (bottom). While constructing networks, quantifying protein activity, defining proteoforms, and considering combinatorial actions are being addressed in specific areas, one future of proteomics requires simultaneous implementation of all these approaches to develop a comprehensive predictive framework of cell and whole tissues for the first time.

Meeting the Scale of the Challenge

Given the vast challenge of capturing protein-level biology (depicted as a hypercube in Figs. 5B and 6A) and the state of measurement, we argue for an increased rate of progress in proteomics. Combinations of new accessible technologies need to provide synergistic data streams to move us beyond census taking and tenuous inferences to far greater understanding of how protein function and how they go awry. The future of proteomics clearly lies in expanding its “dimensions” and building stronger connections across the spatial, temporal, and compositional domains. To achieve major outcomes in biomedicine (Fig. 6C), we should move beyond partial and siloed information on proteins, to an increasingly integrated field (104) providing functional information on a bounded defined proteome.

Fig. 6. Collaborative and big science models for approaching the human proteome in the decade ahead. Scope of the solution needs to match scope of the challenge, if we are to make interactions with the human proteome more deterministic for the goals of biomedical research, including regenerative medicine, more efficient drug development, and early detection of all types of human disease.
Science is inherently a multiscale endeavor (Fig. 6B). In addition to ground-breaking work in individual research laboratories, there are many initiatives building on and maximizing information gain at a larger scale, including the Human Cell Atlas (105), the Human Proteoform Project (39), the Human Proteome Project (6), the Human Protein Atlas (7), and HuBMAP (8), and many organ- or disease-specific consortia such as Kidney Precision Medicine Project (106), Human Tissue Atlas Network (103), and so on. Increasingly, consortia are elevating and integrating proteomics with related fields. Consortia have demonstrated science at a scale not possible in typical single-investigator laboratories, convening multidisciplinary communities and building resources in close collaboration with the research community. Currently, even large teams are only able to generate a small portion of the data needed to comprehensively capture the enigmatic proteome (Fig. 6A). Democratic access to adjacent atlasing projects is essential as well as a balance between building a multiscale scientific approach and implementation of new technologies, including respective training and adoption. However, many consortia are responding with agile management and investigator buy-ins to achieve these goals.

All human diseases involve proteins, and there is an exciting range of new tools providing new insights in protein composition, spatial patterning, and temporal dynamics. A multitude of technologies and multidisciplinary expertise are required (104), and extensive interactions between computational, statistical, clinical, and biology experts will be more important than ever. Proteomics needs to be deeply crossdisciplinary, providing the data and connections to start capturing the complexity of the cell, functional tissue units, and complex traits of an entire person. To accomplish this in proteomics, we need hardened platforms capable of powering quantitative models to reliably connect protein information to disease and unlock precise decision making (Fig. 6C). These hardened platforms will be enabled through a collection of tools, techniques, and statistical approaches. Tremendous advances are possible within the next decade but only with increased level of focus and intention: a “proteomic moonshot” will be needed that can reach this “criticality” with the human proteome.

The National Institutes of Health Office of Strategic Coordination convened a virtual meeting to foster discussion among experts on existing gaps and opportunities within the functional proteomics field. Organized by the National Institutes of Health Office of Strategic Coordination, in collaboration with Workshop Co-Chairs (K. E. B.-J. and N. L. K.) and HuBMAP-funded principal investigators, this meeting engaged proteomics and atlasing experts in discussions designed to (1) identify how functional proteomics tools, methods, and datasets can be integrated to accelerate the development of comprehensive spatiomolecular tissue maps that generate new biological insights and (2) develop a prospective publication that articulates a vision of the field, including state-of-the-art and near-future tools and methods, a roadmap for integrating multiple proteomics data types (e.g., spatial proteomics, single-cell proteomics), and an articulation of the most important knowledge gaps.

Acknowledgments—We thank Nathan Johnson (Pacific Northwest National Laboratory) and Michael Mullowney for assistance in generating figures. The opinions expressed in this article are the authors’ own and do not necessarily reflect the views of the National Institute of Diabetes and Digestive and Kidney Diseases.

Author contributions—K. E. B.-J., T. P. C., R. R. D., A. E. H., R. I., R. T. K., E. L., M. J. M., A. N., G. P. N., P. A. P., K. D. R., S. S., N. S., J. M. S., J. E. V. E., M. V., C. V., D. R. W., and N. L. H. conceptualization; K. E. B.-J., T. P. C., R. R. D., A. E. H., R. I., R. T. K., E. L., M. J. M., A. N., G. P. N., P. A. P., K. D. R., S. S., N. S., J. M. S., J. E. V. E., M. V., C. V., D. R. W., and N. L. H. writing—original draft.

Funding and additional information—C. V. was supported by awards R35GM127089, 75N93019C00052, and the Chan Zuckerberg Initiative; K. E. B.-J. was supported by award UH3 CA255132-03; N. L. K. by UH3 CA246635-02; G. P. N. by U54 HG010426-03; and J. M. S. U54 DK120058-03, all of which are part of the Human Biomolecular Atlas Program. A. N. was supported by R01 CA232517 and Catalyst Award C-088 from the Chicago Biomedical Consortium, United States. A. E. H. was supported by a National Institutes of Health Cancer Moonshot, United States grant (grant no.: R33CA225296) and as a Chan Zuckerberg Biohub Investigator. E. L. was supported by the KAW Foundation (grant nos.: 2016.0204 and 2018.0172), the Swedish Research Council, Sweden (grant no.: 2017-05327), and the Chan Zuckerberg Initiative, United States (grant no.: CZF2019-002448). N. S. was supported by DP2GM123497 and CZF2019-002424, and N. S. and N. L. K. were supported by Allen Distinguished Investigator awards through the Paul G. Allen Frontiers Group. R. T. K. was supported by R01 GM138931.

Conflict of interest—T. P. C. is a Thermo Fisher Scientific Advisory Board member and receives research funding from AbbVie, United States. A. E. H. receives research support from Thermo Fisher Scientific, United States. J. E. V. E. is a Bruker Software Development SAB member and receives support from Thermo Fisher Scientific, Sciex, Canada, Agilent, United States, CellenONE, and Neoteryx. Many authors are involved with private sector endeavors and actively manage competing financial interests. All the other authors declare no competing interests. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Abbreviations—The abbreviations used are: ECM, extracellular matrix; HuBMAP, Human BioMolecular Atlas Program; MS, mass spectrometry; PTM, post-translational modification.
Clarifying the Enigmatic Proteome

REFERENCES

1. Ruggles, K. V., Tang, Z., Wang, X., Grover, H., Askenazi, M., Teubl, J., et al. (2016) An analysis of the sensitivity of proteogenomic mapping of somatic mutations and novel splicing events in cancer. Mol. Cell Proteomics 15, 1060–1071

2. Montecchi-Palazzi, L., Beavis, R., Binz, P. A., Chalkley, R. J., Cottrell, J., Creasy, D., et al. (2008) The PSI-MOD community standard for representation of protein modification data. Nat. Biotechnol. 26, 864–866

3. Smith, L. M., Kelleher, N. L., & Consortium for Top Down, P. (2013) Proteome: a single term describing protein complexity. Nat. Met. 10, 186–187

4. Aebersold, R., Agar, J. N., Amster, I. J., Baker, M. S., Bertozzi, C. R., Boja, E. S., et al. (2018) How many human proteoforms are there? Nat. Chem. Biol. 14, 206–214

5. Zubarev, R. A. (2013) The challenge of the proteome dynamic range and its implications for in-depth proteomics. Proteomics 13, 723–726

6. Adhikari, S., Nice, E. C., Deutsch, E. W., Lane, L., Omenn, G. S., Pennington, S. R., et al. (2020) A high-stringency blueprint of the human proteome. Nat. Commun. 11, 5301

7. Zhu, Y., Scheibinger, M., Ellwanger, D. C., Krey, J. F., Choi, D., Kelly, R. T., et al. (2020) An improved boosting to amplify signal with isobaric labeling in a nanodroplet sample preparation platform. Nat. Commun. 11, 3341

8. Consortium, H. (2019) The human body at cellular resolution: the NIH human biomolecular atlas program. Nat. Methods 16, 178–192

9. Smith, L. M., and Kelleher, N. L. (2018) Proteoforms as the next proteomics currency. Science 359, 1106–1107

10. Nesvizhskii, A. I., and Aebersold, R. (2005) Interpretation of shotgun proteomic data: the protein inference problem. Mol. Cell Proteomics 4, 1419–1440

11. Brannon, T. C., Bosch, J. A., Sanchez, A. D., Udeshi, N. D., Svinika, T., Carr, S. A., et al. (2018) Efficient proximity labeling in living cells and organisms with TurboID. Nat. Biotechnol. 36, 880–887

12. Plubell, D. L., Kall, L., Webb-Roberson, B. J., Bramer, L. M., Ives, A., Kelleher, N. L., et al. (2022) Putting humpty dumpty back together again: what does protein quantification mean in bottom-up proteomics? J. Proteome Res. 21, 891–898

13. Zhang, B., Whiteaker, J. R., Hoofnagle, A. N., Baird, G. S., Rodland, K. D., and Paulovich, A. G. (2019) Clinical potential of mass spectrometry-based proteogenomics. Nat. Rev. Clin. Oncol. 16, 256–268

14. Kelly, R. T. (2020) Single-cell proteomics: progress and prospects. Mol. Cell Proteomics 19, 1739–1748

15. Chen, A. T., Franks, A., and Slavov, N. (2019) Single-cell proteome coverage using narrow-bore packed NanoLC columns and ultrasensitive mass spectrometry. Anal. Chem. 92, 2665–2671

16. Budnik, B., Levy, E., Harmange, G., and Slavov, N. (2018) ScPoE-MS: mass spectrometry of single mammalian cells quantifies proteome heterogeneity during cell differentiation. Genome Biol. 19, 161

17. Brügger, A. D., Thielt, M., Vasilopoulou, C., Ammar, C., Coscia, F., Mund, A., et al. (2022) Ultra-high sensitivity mass spectrometry quantifies single-proteome changes upon perturbation. Mol. Syst. Biol. 18, e10798

18. Slavov, N. (2020) Single-cell protein analysis by mass spectrometry. Curr. Opin. Chem. Biol. 60, 1–9

19. Kelly, R. T. (2020) Single-cell proteomics: progress and prospects. Mol. Cell Proteomics 19, 1739–1748

20. Zhu, Y., Pleihowski, P. D., Zhao, R., Chen, J., Shen, Y., Moore, R. J., et al. (2018) Nanodroplet processing platform for deep and quantitative proteome profiling of 10–100 mammalian cells. Nat. Commun. 9, 582

21. Shao, X., Wang, X., Guan, S., Lin, H., Yan, G., Gao, M., et al. (2018) Integrated proteome analysis device for fast single-cell protein profiling. Anal. Chem. 90, 14003–14101

22. Lombard-Banek, C., Moody, S. A., Manzini, M. C., and Nemes, P. (2019) Microsampling capillary electrophoresis mass spectrometry enables single-cell proteomics in complex tissues: developing cell clones in live Xenopus laevis and Zebrafish embryos. Anal. Chem. 91, 4797–4805

23. Diller, A., Bohlender, P., Dai, M., Filius, M., Howard, C. J., van Kooten, K., et al. (2021) The emerging landscape of single-molecule protein sequencing technologies. Nat. Met. 18, 604–617

24. Callahan, N., Tullman, J., Kelman, Z., and Marino, J. (2020) Strategies for development of a next-generation protein sequencing platform. Trends Biochem. Sci. 45, 76–89

25. Castro-Perez, L., Joe, C., and Dekker, C. (2018) Paving the way to single-molecule protein sequencing. Nat. Nanotechnol. 13, 786–796

26. Swaminathan, J., Boulgakov, A. A., Hernandez, E. T., Bardo, A. M., Bachman, J. L., Marotta, J., et al. (2018) Highly parallel single-molecule identification of proteins in zeptomole-scale mixtures. Nat. Biotechnol. 36, 1076–1082

27. Kelleher, N. L. (2012) A cell-based approach to the human proteome project. J. Am. Soc. Mass Spectrom. 23, 1617–1624

28. Smith, L. M., Agar, J. N., Chamot-Rooke, J., Danis, P. O., Ge, Y., Loo, J. A., et al. (2021) The human proteome project: defining the human proteome. Sci. Adv. 7, eabk0734

29. Duncombe, T. A., Tentori, A. M., and Herr, A. E. (2015) Microfluidics: Reframing biological enquiry. Nat. Rev. Mol. Cell Biol. 16, 554–567

30. Holzner, G., Mateescu, B., van Leeuwen, D., Cereghetti, G., Dechant, R., Stavrakis, S., et al. (2021) High-throughput multiparametric imaging flow cytometry: toward direction-limited sub-cellular detection and monitoring of sub-cellular processes. Cell Rep. 34, 108824

31. Liu, L., Chen, D., Wang, J., and Chen, J. (2020) Advances of single-cell protein analysis. Cells 9, 1271

32. Jain, A., Liu, R., Xiang, Y. K., and Ha, T. (2012) Single-molecule pull-down for studying protein interactions. Nat. Protoc. 7, 445–452

33. Rissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., et al. (2019) Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 27, 595–599

34. Yelleswarapu, V., Buser, J. R., Haber, M., Baron, J., Inapuri, E., and Issadore, D. (2019) Mobile platform for rapid sub-picogram-per-milliliter,
55. Assarsson, E., Lundberg, M., Holmquist, G., Bjorkesten, J., Thorsen, S. B., Rosas-Canyelles, E., Modzelewski, A. J., Geldert, A., He, L., and Herr, A. E. (2020) Assessing heterogeneity among single embryos and single blastomeres using open micro-digestions, and liquid extraction surface analysis for high resolution proteomics of normal and tumor extracellular matrices. *Mol. Cell Proteomics* 11. https://doi.org/10.1074/mcp.M111.014647

51. Yamauchi, K. A., and Herr, A. E. (2017) Subcellular western blotting of single cells. *Microsyst. Nanoeng.* 3, 16079

54. Lundberg, E., and Borner, G. H. H. (2019) Spatial proteomics: a powerful approach to probe cell heterogeneity and extracellular matrix. *Matrix Biol.* 91–92, 152–166

59. He, L., and Herr, A. E. (2016) Single cell-resolution western blotting. *Nat. Protoc.* 11, 1508–1530

53. Kang, C. C., Yamauchi, K. A., Vlassakis, J., Sinkala, E., Dunscombe, T. A., and Herr, A. E. (2016) The extracellular matrix: tools and insights for the “omics” era. *Matrix Biol.* 49, 10–24

56. Uhlen, M., Bandrowski, A., Carr, S., Edwards, A., Ellenberg, J., Lundberg, E., and Herr, A. E. (2016) Comprehensive characterization of glycosylation and glycoexpression of matrisome molecules. *Nature* 14, 743–749

57. Meri-Pham, J., Basak, T., Knuppel, L., Ramanujam, D., Athanason, M., Behr, J., et al. (2019) Quantitative proteomic profiling of extracellular matrix and site-specific collagen post-translational modifications in an in vitro model of lung fibrosis. *Matrix Biol.* Plus 1, 100005

58. Tran, B. O., Miller, P. R., Taylor, R. M., Boyd, G., Mach, P. M., Rose-nzweig, C. N., et al. (2018) Proteomic characterization of dermal interstitial fluid extracted using a novel microencapsulated-assisted technique. *J. Proteome Res.* 17, 479–485

59. Hsu, C. W., Chang, K. P., Huang, Y., Liu, H. P., Hsueh, P. C., Gu, P. W., et al. (2018) Proteomic profiling of paired interstitial fluids reveals dysregulated pathways and salivary NID1 as a biomarker of oral cavity squamous cell carcinoma. *Mol. Cell Proteomics* 18, 1939–1949

60. Piehowski, P. D., Zhu, Y., Bramer, L. M., Stratton, K. G., Zhao, R., Orton, D. J., et al. (2018) DNA barcode-based fluorescence microscopy for spatial omics. *Mol. Cell Proteomics* 20, e1900388

61. Ryan, D. J., Spraggs, J. M., and Caprioli, R. M. (2016) Next-generation technologies for spatial proteomics: integrating ultra-high speed MALDI-TOF and high mass resolution MALDI FTICR imaging mass spectrometry for protein analysis. *Proteomics* 16, 1678–1689

62. Schuender, F., Unterrein, E. M., Ganji, M., and Jungmann, R. (2020) Multiconfigured digital droplet detection of proteins. *Proc. Natl. Acad. Sci. U. S. A.* 116, 4489–4495

63. Wang, Y. T., Shi, T., Srivastava, S., Kagan, J., Liu, T., and Rodland, K. D. (2020) Proteomic analysis of exosomes for discovery of protein biomarkers for prostate and bladder cancer. *Cancers (Basel)* 12, 2335

64. Mathias, B., Mansuri, M. S., Williams, K. R., and Nairn, A. C. (2021) Exosomes as emerging biomarker tools in neurodegenerative and neuropsychiatric disorders-A proteomics perspective. *Brain Sci.* 11, 258

65. Xu, R., Rai, A., Chen, M., Suwakuisiri, W., Greening, D. W., and Simpson, R. J. (2018) Extracellular vesicles in cancer - implications for future improvements in cancer care. *Nat. Rev. Clin. Oncol.* 15, 617–638

66. Taha, I. N., and Naba, A. (2019) Exploring the extracellular matrix in health and disease using proteomics. *Essays Biochem.* 63, 417–432

67. Ryan, D. J., Patterson, N. H., Putnam, N. E., Wilde, A. D., Weiss, A., Perry, W. J., et al. (2019) MultiLESA: integrating autofluorescence microscopy, in situ micro-digestions, and liquid extraction surface analysis for high spatial resolution targeted proteomic studies. *Anal. Chem.* 91, 7578–7585

68. Cohen, L., Cui, N., Cai, Y., Garden, P. M., Li, X., Weitz, D. A., et al. (2020) Single molecule protein detection with attomolar sensitivity using droplet digital enzyme-linked immunosorbent assay. *ACS Nano* 14, 9491–9501

69. Bandrowski, A., Brush, M., Grethe, J. S., Haendel, M. A., Kennedy, D. N., Mehta, A. S., et al. (2019) Extracellular matrix imaging of breast tissue pathologies by MALDI-imaging mass spectrometry. *Proteomics Clin. Appl.* 13, e1700152

70. Naba, A., Clauser, K. R., Hoersch, S., Liu, H., Carr, S. A., and Hynes, R. O. (2012) The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. *Mol. Cell Proteomics* 11. https://doi.org/10.1074/mcp.M111.014647

71. Bingham, G. C., Lee, F., Naba, A., and Barker, T. H. (2020) Spatial-omics: novel approaches to probe cell heterogeneity and extracellular matrix biology. *Matrix Biol.* 91–92, 152–166

72. Bingham, G. C., Lee, F., Naba, A., and Barker, T. H. (2020) Spatial-omics: novel approaches to probe cell heterogeneity and extracellular matrix biology. *Matrix Biol.* 91–92, 152–166

73. Hynes, R. O. (2009) The extracellular matrix: not just pretty brils. *Science* 326, 1216–1219

74. Naba, A., Clauser, K. R., Hoersch, S., Liu, H., Carr, S. A., and Hynes, R. O. (2012) The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. *Mol. Cell Proteomics* 11. https://doi.org/10.1074/mcp.M111.014647

75. Kang, C. C., Yamauchi, K. A., Vlassakis, J., Sinkala, E., Dunscombe, T. A., and Herr, A. E. (2016) The extracellular matrix: tools and insights for the “omics” era. *Matrix Biol.* 49, 10–24

76. Bingham, G. C., Lee, F., Naba, A., and Barker, T. H. (2020) Spatial-omics: novel approaches to probe cell heterogeneity and extracellular matrix biology. *Matrix Biol.* 91–92, 152–166

77. Bingham, G. C., Lee, F., Naba, A., and Barker, T. H. (2020) Spatial-omics: novel approaches to probe cell heterogeneity and extracellular matrix biology. *Matrix Biol.* 91–92, 152–166
proteins from tissue sections at 100-mum spatial resolution. Nat. Commun. 11, 8
90. Pankow, S., Martinez-Bartolome, S., Bamberger, C., and Yates, J. R. (2019) Understanding molecular mechanisms of disease through spatial proteomics. Curr. Opin. Chem. Biol. 48, 19–25
91. Bahariou, H., Canete, N. P., Cunningham, A. L., Harman, A. N., and Patrick, E. (2019) Mass cytometry imaging for the study of human diseases-applications and data analysis strategies. Front. Immunol. 10, 2657
92. Spraggins, J. M., Rizzo, D. G., Moore, J. L., Rose, K. L., Hammer, N. D., Skaar, E. P., et al. (2015) MALDI FTICR IMS of intact proteins: using mass accuracy to link protein images with proteomics data. J. Am. Soc. Mass Spectrom. 26, 974–985
93. Yin, R., Burnum-Johnson, K. E., Sun, X., Dey, S. K., and Laskin, J. (2019) High spatial resolution imaging of biological tissues using nanospray desorption electrospray ionization mass spectrometry. Nat. Protoc. 14, 3445–3470
94. Van de Plas, R., Yang, J., Spraggins, J., and Caprioli, R. M. (2015) Image fusion of mass spectrometry and microscopy: a multimodality paradigm for molecular tissue mapping. Nat. Met. 12, 366–372
95. Clift, C. L., Drake, R. R., Mehta, A., and Angel, P. M. (2021) Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin-embedded tissue sections. Anal. Bioanal. Chem. 413, 2709–2719
96. [preprint] Mund, A., Coscia, F., Hollandi, R., Kovács, F., Kriston, A., Brunner, A. D., et al. (2021) Al-driven Deep Visual Proteomics defines cell identity and heterogeneity. bioRxiv. https://doi.org/10.1101/2021.01.25.427969
97. Jones, M. A., Cho, S. H., Patterson, N. H., Van de Plas, R., Spraggins, J. M., Boothby, M. R., et al. (2020) Discovering new lipidomic features using cell type specific fluorophore expression to provide spatial and biological specificity in a multimodal workflow with MALDI imaging mass spectrometry. Anal. Chem. 92, 7079–7086
98. Qin, Y., Huttlin, E. L., Winsnes, C. F., Gosztyla, M. L., Wacheul, L., Kelly, M. R., et al. (2021) A multi-scale map of cell structure fusing protein images and interactions. Nature 600, 536–542
99. Bhalla, U. S., and Iyengar, R. (1999) Emergent properties of networks of biological signaling pathways. Science 283, 381–387
100. Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., et al. (2000) Gene ontology: tool for the unification of biology. The gene Ontology Consortium. Nat. Genet. 25, 25–29
101. Yang, X., Coulombe-Huntington, J., Kang, S., Sheynkman, G. M., Hao, T., Richardson, A., et al. (2016) Widespread expansion of protein interaction capabilities by alternative splicing. Cell 164, 805–817
102. [preprint] Jens Hansen, R. S., Menon, R., Eadon, M. T., Lake, B. B., Steck, B., Dobi, D., et al. (2020) Towards building a smart Kidney atlas: network-based integration of multimodal transcriptomic, proteomic, metabolomic and imaging data in the Kidney precision medicine project. bioRxiv. https://doi.org/10.1101/2020.07.23.216507
103. Rozenblatt-Rosen, O., Regev, A., Oberdoerffer, P., Naity, T., Hupalowska, A., Rood, J. E., et al. (2020) The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution. Cell 181, 236–249
104. Vitrinel, B., Koh, H. W. L., Muygan Kar, F., Maity, S., Rendleman, J., Choi, H., et al. (2019) Exploiting interdata relationships in next-generation proteomics analysis. Mol. Cell Proteomics 18, S5–S14
105. Rozenblatt-Rosen, O., Shin, J. W., Rood, J. E., Hupalowska, A., Human Cell Atlas, S., Technology Working, G., et al. (2021) Building a high-quality human cell atlas. Nat. Biotechnol. 39, 149–153
106. de Boer, I. H., Alpers, C. E., Azeloglu, E. U., Balis, U. G. J., Barasch, J. M., Barisoni, L., et al. (2021) Rationale and design of the Kidney precision medicine project. Kidney Int. 99, 498–510

Clarifying the Enigmatic Proteome